Schizophrenia: The drug deadlock.
Alison
A
Abbott
D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003024:Clozapine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D003071:Cognition / Q000187:drug effects; D065127:Dopamine D2 Receptor Antagonists; D004353:Drug Evaluation, Preclinical / Q000379:methods; D004345:Drug Industry / Q000191:economics / Q000639:trends; D006801:Humans; D010546:Perphenazine / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000150:complications / Q000188:drug therapy; D044402:Receptor, Serotonin, 5-HT2A / Q000378:metabolism; D017448:Receptors, Dopamine D2 / Q000378:metabolism; D012559:Schizophrenia / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology / Q000503:physiopathology; D058830:Serotonin 5-HT2 Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use
D014150:Antipsychotic Agents; D065127:Dopamine D2 Receptor Antagonists; D044402:Receptor, Serotonin, 5-HT2A; D017448:Receptors, Dopamine D2; D058830:Serotonin 5-HT2 Receptor Antagonists; D010546:Perphenazine; D003024:Clozapine